Tianjin Chase Sun Pharmaceutical News

Hongri Pharmaceutical (300026) 2023 Interim Report Review: Profits recovered strongly in the second quarter and are looking forward to the release of formula granules

國海證券Aug 30, 2023 00:00

Red Sun Pharmaceutical (300026) 2023 Quarterly Review Report: Short-term performance is pressured and sales of formula pellets are expected to resume

國海證券May 2, 2023 00:00

Red Sun Pharmaceutical (300026): Short-term performance is under pressure, and the recovery of the formula granule business is imminent

華鑫證券Apr 27, 2023 00:00

Red Sun Pharmaceutical (300026): Formulated granules must have net blood growth under short-term pressure, impressive growth, and formula particles are expected to reach an inflection point in growth in 2023

方正證券Apr 2, 2023 00:00

Red Sun Pharmaceutical (300026) Company Incident Review Report: Formulation Particle Standards Are Steadily Improving, Expecting Performance Recovery

華鑫證券Mar 31, 2023 16:37

Red Sun Pharmaceutical (300026): Performance is in line with expectations, and the formula granule business is expected to recover strongly

國聯證券Mar 31, 2023 09:51

Hongri Pharmaceutical (300026) Performance Report Review: Continued increase in the number of granule standards for traditional Chinese medicine formulations and expectations for performance flexibility

國海證券Mar 1, 2023 00:00

League of Nations Securities: The increase in national standards is expected to accelerate the growth of formula particles and give the industry a “better than the market” rating

Zhitong FinanceFeb 2, 2023 10:46

Hongri Pharmaceutical (300026) 2022 Third Quarterly Report Review: The National Standard Issued Slows Pressure on Formulated Particles

國信證券Nov 17, 2022 00:00

Red Sun Pharmaceutical (300026): The insufficient number of national and provincial standards affects the volume of formula particles released and waits for the industry to reach an inflection point in operation

方正證券Oct 25, 2022 00:00

Hongri Pharmaceutical (300026): Short-term performance was pressured and waited for marginal improvement in the second half of the year due to the switch to national standards for formula granules due to the epidemic

方正證券Aug 31, 2022 00:00

Red Sun Pharmaceutical (300026): Profit for formula pellets in the first half of the year, short-term pressure, long-term optimism, and high growth rate after standard switching is completed

東興證券Aug 31, 2022 00:00

Hongri Pharmaceutical (300026) comment report: the performance is basically in line with the expected growth of formula particles after the implementation of the national standard.

國海證券Aug 30, 2022 00:00

Red Sun Pharmaceutical Industry (300026): new opportunities for the development of formula granules under the reform of GB

華鑫證券Jun 29, 2022 15:21

Hongri Pharmaceutical (300026): the epidemic situation and the standard conversion of formula granules put short-term pressure on the performance. The volume and price of formula granule business is expected to rise in the second half of the year.

方正證券May 4, 2022 00:00

Hongri Pharmaceutical (300026): 42% strong growth of formula particles, 37% recovery high growth of finished pharmaceutical plate

方正證券Apr 2, 2022 00:00

Hongri Pharmaceutical (300026): Xuebijing sales increase, research and development to create a new growth point

東興證券May 7, 2020 00:00

Red Sun Pharmaceutical (300026) event tracking: the change of the actual controller to Yao Xiaoqing is good for the long-term development of the company

銀河證券Jul 10, 2018 00:00

Comments on Red Sun Pharmaceutical (300026) Annual report: poor performance of main products and continuous progress in R & D

東方證券Apr 2, 2018 00:00

Red Sun Pharmaceutical (300026): KB enters the II/III phase of clinical Chinese medicine formula granules are expected to come out of the trough

財通證券Mar 12, 2018 00:00